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Abstract
Uterine fibroids are the commonest benign tumours of women and affect all
races with a cumulative lifetime risk of around 70%. Despite their high
prevalence and the heavy economic burden of treatment, fibroids have
received remarkably little attention compared to common female malignant
tumours. This article reviews recent progress in understanding the biological
nature of fibroids, their life cycle and their molecular genetic origins. Recent
progress in surgical and interventional management is briefly reviewed, and
medical management options, including treatment with selective progesterone
receptor modulators, are also discussed.
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Introduction
Uterine fibroids (leiomyomas) are benign monoclonal tumours 
of smooth muscle, taking origin in the myometrium. They are 
the commonest benign tumours of the uterus, and are typically 
round well-circumscribed masses. They are usually multiple, and 
can range in size from a few millimetres to massive growths of 
20cm diameter and more. The aetiology is largely unknown, but 
they are oestrogen- and progesterone-dependent tumours, very rare 
before menarche, common in reproductive life, and frequently 
regress in size after menopause1.
By age 50, it is estimated that 70% of women will have one or 
more uterine fibroids, with around 30% of patients symptomatic 
and requesting treatment. Women of all races are affected, but 
fibroids are commoner, and develop at an earlier age, in women 
of African origin2. By age 35 years, 60% of African-American 
women will have fibroids, compared to 40% in Caucasian women 
of the same age. Other risk factors include age (increasing inci-
dence with age up to the menopause, then usually decreasing 
in size), nulliparity, genetic factors, early menarche, caffeine, 
alcohol, obesity and hypertension3.
Symptoms of fibroids are abnormal uterine bleeding, pelvic 
pain, dyspareunia, obstructive effects on bladder or rectum, and 
infertility. Fibroid size does not necessarily determine the severity 
of clinical symptoms. In a large online survey conducted in eight 
countries with at least 2,500 participants in each country (4000 
in USA), 59.8% of women with a diagnosis of uterine fibroids 
self-reported heavy and prolonged vaginal bleeding compared to 
37.4% in those without fibroids4. Pelvic pain at various times 
in the menstrual cycle and during sexual intercourse were also 
significantly increased in fibroid patients. Excessive vaginal 
blood loss can lead to severe anaemia which can even be life- 
threatening, yet some patients do not recognise the severity of the 
problem, may consider their blood loss to be normal, and do not 
seek help5.
Uterine fibroids place a large economic burden both on the women 
who suffer from them, and on the health systems and socie-
ties in which they live. Symptoms may lead to significant loss 
of working time, and in a large survey 24% of women perceived 
symptoms as a contributing factor in failure to achieve career 
aspirations6. Direct surgical costs alone are high – in the USA, 
200,000 hysterectomies are performed annually for fibroids7, and 
when medications, inpatient and outpatient hospital attendances 
are added, the annual costs are estimated at between 4–9 billion 
US dollars8. These costs do not include lost work time, and other 
consequences such as spontaneous abortions, pre-term delivery 
and Caesarean sections.
Imaging techniques are the mainstay of diagnosis, with transab-
dominal or transvaginal ultrasound the most commonly used 
modality, as it is widely available, inexpensive and usually defini-
tive in diagnosis. MRI may be used to delineate the number, size 
and location of fibroids in certain cases, and hysteroscopy may 
be useful to distinguish between subendometrial fibroids and 
large endometrial polyps. Neither imaging nor hysteroscopic 
methods are currently reliable in distinguishing benign fibroids 
from sarcomatous uterine tumours.
Surgical treatment takes the form of hysterectomy or myomec-
tomy, the choice depending on the size, number and extent of 
fibroids, and on the patient’s wishes with regard to fertility. 
Hysteroscopic or laparoscopic myomectomy are considered safe 
and effective options, but laparoscopic hysterectomy is usually 
still the standard surgical option in women who do not wish to 
retain fertility3. It should be noted, however, that hysterectomy is 
not free from short term and long term sequelae – 1 in 30 women 
suffers a major adverse event, and mortality may be between 
0.4-1.1 per 1000 operations9. Non-surgical interventional treat-
ments also include uterine artery embolization (UAE), and high- 
frequency MR-guided focussed ultrasound surgery.
Until recently, medical management of fibroids was largely 
confined to symptomatic treatment of pain and bleeding, and 
the use of gonadotropin-releasing hormone (GnRH) analogues. 
The latter lead to a hypo-oestrogenic state, fibroids undergo 
shrinkage, and blood loss and anaemia can be corrected, but 
duration of treatment is limited by side effects of menopausal 
symptoms and loss of bone mineral density.
More recently, a newer group of agents, the selective proges-
terone receptor modulators (SPRMs), have shown considerable 
effectiveness in the medical management of fibroid patients10. As 
well as their effects on fibroid shrinkage, in most patients SPRM 
treatment leads to rapid control of heavy menstrual bleeding, 
and correction of anaemia. Oestrogen levels remain at around 
mid-follicular levels, and, as a consequence, menopausal symptoms 
and bone loss are not encountered regularly.
Histopathology
Fibroids are correctly known as leiomyomas, being benign tumours 
of smooth muscle, taking origin in the myometrium. As the 
fibroid grows, the cells differentiate into four different cell 
types that can be reliably characterised: smooth muscle cells, 
vascular smooth muscle cells and two different subpopulations 
of fibroblasts. It has been shown that all four cell types derive from 
a single clonal origin11.
Macroscopically, the lesions are usually multiple, pale, firm 
and rubbery, with a whorled cut surface, well demarcated from 
adjacent myometrium. There may be areas of mucoid change, 
haemorrhage, or necrosis and calcification visible on gross 
inspection. Microscopically, they are composed of spindle cells 
arranged in fascicles that interweave to form a circumscribed 
lesion. Mitotic activity may be observed, but there are usually less 
than 5 mitoses per 10 high power fields (HPF), and no atypical 
forms. Mitotic activity is significantly higher in the secretory 
phase of the cycle12, an observation that suggests importance 
of progesterone and its receptor PR in fibroid growth. There is a 
great degree of variability in the amount of extracellular matrix 
and collagen in fibroids, leading to considerable heterogeneity in 
histological patterns. Degenerative changes may be superimposed, 
including hyaline and myxoid change, hydropic degeneration, 
necrosis and calcification.
Notwithstanding this variability in the usual type of leiomyoma, 
there are several distinct histological variants that may cause some 
diagnostic difficulty to the histopathologist. Cellular leiomyoma 
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is significantly more cellular than the usual type, but shows no 
nuclear atypia, a low mitotic index (4 or less mitoses per 10 HPF), 
and no necrosis. Leiomyoma with bizarre nuclei (previously 
termed atypical or symplastic leiomyoma) characteristically 
shows highly pleomorphic extremely bizarre nuclei, often in a 
background of more typical leiomyoma cells. Mitotic activity is 
usually low, but karyorrhexis may mimic atypical mitoses, and 
the histopathologist must be cautious not to diagnose sarcoma, 
as these are benign lesions. Mitotically active leiomyoma shows 
a high mitotic index (>10 mitoses per 10 HPF), but no other 
concerning features, with an absence of nuclear atypia and 
necrosis. These are likely endocrine related, as they are seen in 
the reproductive age group, and have been reportedly associated 
with hormone therapy. Dissecting (‘cotyledenoid’) leiomyoma 
is a rare variant which shows locally invasive growth sometimes 
extending outwith the uterus, often with a prominent degree of 
hydropic change. Diffuse leiomyomatosis is a rare condition in 
which multitudes of benign-appearing leiomyomatous nodules 
blend with uterine smooth muscle, and may extend beyond the 
uterus into the peritoneal cavity forming tumour-like nodules, 
grossly resembling disseminated gynaecological cancers. The 
process is benign, and surgical removal is curative.
An uncommon but troublesome group of tumours show 
histological appearances that may arouse concern about possible 
leiomyosarcoma, but which fall short of definitively malignant 
lesions. Described as atypical smooth muscle neoplasms, or smooth 
muscle tumours of uncertain malignant potential (STUMP), such 
lesions show an intermediate level of mitotic activity (5 – 10 mitoses 
per 10 HPF), variable necrosis or myxoid change, and a degree 
of nuclear atypia, sometimes with epithelioid cell morphology. 
The prognosis of such tumours is unpredictable, but recur-
rence occurs in approximately 10 – 15% of cases. A promising 
approach to prediction of outcome in such lesions has recently 
been described13 in which comparative genomic hybridisation 
was used to clearly stratify a series of uterine STUMP into two 
separate prognostic groups: one with prognosis similar to 
leiomyoma, the other with outcome similar to low grade leiomy-
osarcoma.
Leiomyosarcoma is a frankly malignant neoplasm of smooth 
muscle origin. Whilst most appear to occur de novo from 
myometrium, there is evidence that up to 20 – 30% may arise from 
pre-existing benign smooth muscle tumours (see below). This 
must be a rare event, considering how common benign fibroids 
are and the rarity of leiomyosarcoma.
Life Cycle of Fibroids
A careful morphological review14 led to the hypothesis that 
fibroid formation may represent an abnormal response to injury. 
This proposes that normal myometrium may be subject to 
repeated injury through vasoconstriction and hypoxia during 
menstruation, and that development of fibroids may repre-
sent a reaction to that injury. There are intriguing parallels with 
processes of wound healing, keloid formation and even the reac-
tion to injury occurring in blood vessels in the formation of 
atherosclerosis. Additional evidence from Ciarmela’s group15 
suggests the action of an inflammatory trigger to excessive 
production of extracellular matrix by activated myofibroblastic 
cells in fibroids.
Uterine fibroids have a self-limited life cycle of proliferative 
growth, synthesis of collagen, increasing deposition of extracellu-
lar matrix, decreasing vascularity, and ultimately senescence and 
involution through ischaemic degeneration and inanition14. 
Four phases in the life cycle of fibroids have been described, 
defined somewhat arbitrarily and representing a continuous 
process, progressing through phenotypic transformation of the 
proliferating contractile myocyte and evolutionary selection of 
a single clone. There is increasing deposition of collagen, and 
as the process of fibroid growth and development evolves, the 
phenotype of the clonally proliferating myocytes changes from 
contractile to collagen synthesising, with significant elaboration of 
extracellular ground substance. Myocytes become separated 
from vessels by increased amounts of extracellular matrix, and 
angiogenesis does not keep up with the increasing size of the 
fibroid. Ischaemia eventually occurs, and there is cessation of 
myocyte proliferation and cellular atrophy. In the end stage, there 
is abundant hyaline matrix enclosing islands of atrophic myo-
cytes, and there may be necrosis and calcification. Processes of 
cell death, resorption and reclamation now occur, termed ‘inanosis’ 
by the authors. These differ from necrosis and apoptosis in 
their morphology, in their long, protracted durations, and in the 
absence of any inflammatory or phagocytic response to cell death.
Genetic and Molecular Aspects of Aetiology
Several lines of evidence point to a significant genetic predis-
position to development of uterine fibroids. Women with first 
degree relatives having fibroids have an increased incidence16, and 
monozygotic twins have higher concordance for fibroids than 
dizygotic17. Up to around 50% of uterine leiomyomas show 
cytogenetic alterations, including trisomy of chromosome 12, 
deletions in the long arm of chromosome 7, rearrangements of 
12q15 and mutations in MED12 and HMGA2 genes. There is 
evidence for the existence of a population of cells with stem 
or progenitor cell characteristics, which can be isolated from 
normal myometrium and from leiomyoma tissues18. It is hypoth-
esised that activating mutations occurring in this cell type 
give rise to the clonal population of myocytes making up the 
leiomyoma. Intriguingly, a recent study using whole genome 
sequencing of uterine leiomyomas showed that multiple fibroid 
nodules within the uterus can be clonally related, indicating 
a single cell origin of multiple leiomyomas19. This study also 
reported the occurrence in fibroids of complex chromosomal 
rearrangements resembling chromothripsis, apparently occurring 
as a single chromosomal shattering event with up to 20 or more 
double-stranded breaks, followed by random reassembly. The 
authors suggest that tumour formation occurs when reassembly 
leads to the juxtaposition and activation of tumour-promoting 
genes.
Epigenetic mechanisms are also likely to have a key role in fibroid 
formation. Several tumour suppressor genes have been shown to 
be abnormally hypermethylated in fibroids compared to adjacent 
myometrium20, as are collagen-related genes and a subset of ER 
response genes21.
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MED12
Exome sequencing a small series of leiomyoma tissues identified 
a high frequency of somatic mutations in MED12 (also known 
as mediator complex subunit 12) gene22, and a subsequent larger 
survey of 225 fibroids from 80 patients identified MED12 
mutations in 70%23, making MED12 the most frequently altered 
gene in leiomyomas. MED12 is an X-linked gene that encodes 
a subunit of the mediator complex that is central to regulation 
of transcription, and is a crucial element in canonical WNT 
signalling, known to interact with β-catenin. Most mutations occur 
in a highly conserved area of exon 2 of the gene, with around 
50% occurring as mis-sense mutations of codon 44, and it has 
been suggested that these may represent ‘gain of function’ 
alleles24. Less frequently, mutations occur at the intron 1/exon 
2 boundary, and even more rarely in exon 1, respectively. There 
is an inverse correlation between presence of MED12 mutation 
and leiomyoma size, suggesting that lesions of differing sizes 
may have different aetiological pathways. MED12 mutations 
seem relatively specific for leiomyoma, and also occur in around 
10 – 20% of leiomyosarcomas25,26. However, the same type of 
mutation has also been found in chronic lymphocytic leukaemia27, 
and malignant phyllodes tumour of the breast28.
HMGA2
Cytogenetically visible alterations in 12q14-15 and 6p21 have 
been observed in leiomyomas, and rearrangements at these 
loci map to genes encoding high mobility group proteins HMGA2 
and HMGA1, respectively, leading to their overexpression. 
Overexpression of HMGA2 was found to be the second most 
frequent genetic alteration in leiomyomas, being present in 
7.5–10%26. Overexpression was exclusively found in leiomyomas 
that did not have mutation of MED12, indicating the likeli-
hood of two separate and mutually exclusive pathways of fibroid 
development29. Each group has differing global gene expression 
profiles, and further evidence indicates that leiomyomas with 
alterations of MED12 and HMGA2 show different behaviours. In 
a study of 289 fibroids from 120 patients, it was found that over 
85% of MED12 mutated lesions occurred as multiple uterine 
nodules, whereas 70% of HMGA2 mutated lesions were single 
nodules30.
Rarely, uterine leiomyomas may be part of the hereditary 
leiomyomatosis and renal cell cancer syndrome caused by 
heterozygous germline mutations in the fumarate hydratase 
(FH) gene. The disorder has an autosomal dominant pattern of 
inheritance, and is clinically characterised by the occurrence of 
multiple (10 to over 100) cutaneous leiomyomas, often painful, 
occurring in a segmental pattern on trunk and extremities. 
Leiomyomas in this syndrome present a unique global gene 
expression profile, without overlap with those associated with 
MED12 or HMGA2 mutations23.
Advances in surgical and interventional management 
of fibroids
For many years, hysterectomy has been the treatment of choice 
for uterine fibroids, and is still the most commonly used 
treatment. Laparoscopic hysterectomy rates may exceed 90% 
in some departments, but other surgical and interventional 
treatments are increasingly available3. The treatment selected 
often depends on the patient’s age, her willingness to undergo 
what is perceived to be a major surgical procedure, and her desires 
for future fertility or complete amenorrhoea. Guidelines exist in 
the literature, but there are few clinical trials comparing different 
treatments.
Hysteroscopic myomectomy is suitable for fibroids of certain 
sizes and locations, being most suited to smaller pedunculated 
submucous lesions which can be removed by transection of the 
base with a resectoscopic loop. Some smaller intramural fibroids 
may be removed hysteroscopically in one- or two-step procedures 
that involve slicing the lesion into chips, or use of an intrauterine 
morcellator.
Laparoscopic myomectomy is technically more challenging 
than open laparotomy, but reproductive outcomes are similar, 
post-operative morbidity is much less and recovery times much 
shorter. Fibroids are usually removed with the aid of a power 
morcellator. Morcellation has the drawback of potential perito-
neal dissemination of unrecognised uterine sarcoma, and although 
the risk may have been overemphasised, it remains a theoretical 
concern. While recognising the difficulty of histopathological 
diagnosis in specimens obtained after power morcellation, a 
large series of 10,731 laparoscopic hysterectomies31 found the 
incidence of malignancy in morcellated surgical specimens to be 
0.06% (six cases).
Non-surgical interventional treatments include UAE, an effec-
tive and safe alternative to hysterectomy in women in whom 
retention of fertility is not a priority, although there is little 
evidence of any poorer fertility outcome with UAE compared to 
myomectomy32. Although this treatment has similar outcomes 
to surgery in terms of patient satisfaction, risk of major com-
plications and fertility outcome, there is a higher rate of minor 
complications and subsequent surgical intervention within two to 
five years, with between 15 and 32% of women requiring further 
surgery33.
High frequency magnetic resonance guided focussed ultrasound 
is a technique whereby ultrasonic energy is directed with MR 
guidance to within the fibroid, where thermal ablation by 
coagulative tissue necrosis occurs. The method is not yet widely 
used, as it is currently expensive, is suitable for only a minority 
of fibroid patients, and has unknown implications for future 
fertility34.
Medical management of fibroids
First line management of uterine fibroids usually involves 
symptomatic treatment of heavy menstrual bleeding, with use of 
inexpensive non-steroidal anti-inflammatory drugs (NSAIDs), 
antifibrinolytic agents including tranexamic acid, or contraceptive 
steroids including the levonorgestrel intrauterine system (Mirena), 
the latter only suitable for patients in whom the uterine cavity is 
not distorted by fibroids35. Although bleeding symptoms may be 
alleviated, there is no evidence of fibroid shrinkage, indeed 
there is reason to believe that progestogen therapy may induce 
proliferation of leiomyoma cells. Shrinkage of fibroids can, however, 
be achieved by treatment with GnRH agonists, or with SPRMs.
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Continuous administration of a GnRH agonist leads to 
downregulation of pituitary GnRH receptors, with consequent 
decreased production of FSH and LH, and subsequently of 
ovarian steroids. Treatment for three to six months has been 
shown to result in decreased uterine and fibroid size, and duration 
of hospital stay after surgery36. However, the hypo-oestrogenic 
state induced by GnRH agonist treatment results in menopau-
sal side effects, including loss of bone mineral density, that limit 
treatment duration usually to six months or less. While there is 
some evidence that add-back therapy can offer some advantages 
in these situations37, unwanted side effects of therapy with GnRH 
analogues remain a problem. It has also been observed that rapid 
regrowth of fibroids occurs after cessation of GnRH treatment.
Selective progesterone receptor modulators in management
The advent of SPRMs has opened a new and promising avenue 
of treatment for many patients. The effectiveness of these agents 
is based on the premise that fibroids show progesterone depend-
ence, and blockade or modulation of progesterone activity at PR 
results in cessation of proliferation and induction of apoptosis 
in the fibroid, with consequent shrinkage. SPRMs also rapidly 
induce amenorrhoea in most patients, providing additional 
welcome symptomatic relief of bleeding. The mechanism whereby 
amenorrhoea is induced remains unknown, but it is believed 
to be a direct effect on the endometrium. Clinical trials of 
SPRMs in treatment of fibroids have been carried out using a 
variety of agents, including mifepristone38, telapristone acetate39, 
asoprisnil40, ulipristal acetate41, and vilaprisan42.
SPRMs induce characteristic morphological changes in 
endometrium that have not been observed with other pharma-
ceutical agents, and have been designated PAEC (progesterone 
receptor modulator-associated endometrial changes43). Uninter-
rupted treatment with SPRMs for six months or more induces 
endometrial thickening, and to avoid associated complications, 
successful clinical trials have utilised an interrupted regime 
of three months on treatment followed by one month off, with 
menstrual shedding of the endometrium.
In 2012, following large Phase III clinical trials, ulipristal acetate 
was the first SPRM to be granted a licence from the European 
Medicines Agency for use in the pre-surgical treatment of fibroids, 
and it is now being used in many countries worldwide. Early 
Phase III trials showed that one course of 5 mg ulipristal acetate 
orally for 12 weeks led to a mean 20–35% reduction in fibroid 
volume, and that the reduction in volume was maintained for up 
to 6 months following end of treatment10,41. Treatment was also 
associated with rapid control of uterine bleeding in over 80% of 
patients. Subsequent trials showed that further fibroid shrinkage 
occurred with repeated courses, with median reduction in fibroid 
volume of 71.8% after 4 courses44. Histopathological assessment 
of fibroids resected after ulipristal acetate treatment has shown 
induction of apoptosis and remodelling of extracellular matrix in 
the lesions45. Subsequent studies established endometrial safety 
of up to eight courses, using a repeated interrupted regime of 
three months treatment followed by one month off treatment with 
menstrual shedding46. As oestrogen levels are not suppressed on 
treatment, menopausal symptoms and bone mineral loss are not 
significant clinical issues. Ulipristal acetate is now licensed for 
repeated 12 week courses, but must be prescribed with a one month 
break between courses, to avoid adverse endometrial effects. A 
retrospective analysis of 21 patients who enrolled in two of the 
clinical trials of ulipristal acetate, who had myomectomies and 
wished pregnancy after treatment, reported successful pregnancies 
in 15 patients (71%), with birth of 13 healthy babies and 6 early 
miscarriages47.
What Does the Future Hold?
After many years of relative neglect, the pathogenesis of uterine 
fibroids is now receiving more attention, and we are beginning 
to gain a foothold in understanding the molecular genesis of 
these very common and troublesome tumours. These are the first 
necessary steps in the journey towards effective non-surgical 
treatment and perhaps even prevention. Excellent progress has 
been made in the laparoscopic surgical treatment of fibroids 
and this will continue, perhaps with robotic and other develop-
ments. However, the long-term goal must be to develop effective 
medical treatments, and the advent of SPRMs opens up the 
prospect of safe therapy without the troublesome side effects of 
previous medical treatments, with the potential to greatly improve 
the quality of life of huge numbers of women around the world.
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